FDA 483 - Marc Miller, M.D. - March 08, 2019

An FDA inspection of Marc Miller, M.D., a clinical investigator in New York, revealed one significant observation. The firm failed to ensure that the sponsor received updated financial disclosure information from participating investigators when a study's funding source changed. This indicates a lapse in maintaining complete and accurate financial records related to clinical studies.